Abstract: A system (1) for issuing parking permits in pay-for-parking zones, for example, permits for short-term street parking in local authority areas comprises a central control terminal (2) which controls operation of the system. Clients wishing to avail of the system (1) obtain a visual display device (3) for mounting in his or her motor vehicle for displaying the expiry time of the parking permit, and register with the system (1). The central control terminal (2) is controlled by a computer (7) and each client of the system is identified by his or her mobile telephone number, which is cross-referenced with an address code of the visual display device (3) in an ID memory (8) of the central control terminal (2). Each client of the system, in general, maintains a positive credit balance in his or her account in an account memory (14) of the central control terminal (2).

Abstract: The invention provides a cementitious composition comprising at least one sulphoaluminate cement which comprises a sulphoaluminate salt of an alkaline earth metal, the cementitious composition being essentially free of other cementitious components. Preferably the at least one sulphoaluminate salt of an alkaline earth metal comprises calcium sulphoaluminate and the cementitious composition additionally comprises at least one further salt of an alkaline earth metal, preferably calcium sulphate. The invention also provides a method for the encapsulation of materials, the method comprising treating the materials with the said at least one cementitious composition. Preferably, the materials which are encapsulated according to the method of the invention comprise waste materials generated in the nuclear processing industry comprising amphoteric reactive metals.

Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Abstract: Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents —(CRnaRnb)n—; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 and R4 each independently represent hydrogen or C1-6alkyl; R7 represents hydrogen or C1-6alkyl; R8 represents hydrogen or C1-6alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.

Abstract: Compound of formula (I): and salts and solvates thereof, a process for its preparation, pharmaceutical formulations containing it and its use in therapy.

Abstract: Processes for the preparation of a compound of formula (IIIA) or a salt thereof are disclosed.

Abstract: A compound selected from the group consisting of a 5,6-dihydro-&agr;-pyrone of formula (I): wherein bond a is oriented either or ; X is O or NH; R1 is selected from the group consisting of: a group R3(O)C— wherein R3 is selected from the group consisting of: (i) a group of formula R4—CH═CH— wherein R4 is C1-C20 alkyl, C2-C20 alkenyl, an aryl group, or a 5- or 6-membered unsaturated heterocyclic ring containing one or two O, N or S atoms, (ii) C2-C20 alkyl; and (iii) an aryl group or a substituent which is a fused ring system of formula (1) or (2):  wherein each of R′ and R″, which are the same or different and may occupy any position on ring a or ring b of said fused ring system, is H or C1-C6 alkyl; a group ArCH2— wherein Ar is an aryl group; and a group R5O—CH2— wherein R5 is C1-C6 alkyl optionally interrupted by one or two O atoms; and R2 is CH3 or, when R1 is a group of formula (A) as defined below, R2 i